Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA bioterrorism programs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CDER bioterrorism efforts will be coordinated by the Office of Review Management's new Office of Pediatric Drug Development and Special Initiatives, under the direction of FDA's Dianne Murphy, MD. CDER efforts will focus on development of drugs to treat smallpox and plague, while CBER will focus on fostering development of new vaccines for smallpox and anthrax. In the wake of the Sept. 11 terrorist attacks, FDA bioterrorism programs will receive a higher priority with hopes for a staffing increase in 2002 as more government resources become available. The Office of Science Coordination and Communication's Andrea Meyerhoff directs the overall FDA bioterrorism effort
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel